Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due…
Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and…
Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory DiseasesWALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic…
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to…
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical…
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of…
VANCOUVER, British Columbia, March 19, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7)…
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the…
DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…
Four healthy subjects dosed with RECCE® 327 at 3,000mg over 20 minutesData received from this cohort will support preparations for…